Ungstöd Sverige AB has been acquired by Nytida AB
Nytida AB has acquired Ungstöd Sverige AB for US$10 million.
Ungstöd, founded in 2007 and headquartered in Stockholm, is a non-institutional care provider offering services requiring state permits in accordance with the Social Services Act (sv. SoL) and the Act Concerning Support and Service for Persons with Certain Functional Impairments (sv. LSS). Ungstöd is a specialized care provider offering support and care for children with social and psychiatric problems.
Nytida AB is a leading player in the Swedish market offering support and assistance to people with medical and social disabilities. The company, with 250 established operations throughout the country and sales of approximately US$117 million, offers a wide range of non-institutional care services.
“Avantus has supported us throughout the whole process, with great commitment and sector expertise, and has played a pivotal role in what has become an outcome far beyond our expectations”, said Emil Wallgren, co-founder and CEO, Ungstöd.
Oaklins' team in Sweden advised the seller in this transaction.
Prata med transaktionsteamet
Relaterade transaktioner
MEDIK Hospital Design Group has been acquired by STERIS
The private shareholders of MEDIK Hospital Design Group have sold their shares to STERIS plc. Together, MEDIK and STERIS will expand their offerings for hospitals and ambulatory surgery centers worldwide. MEDIK’s solutions ideally complement STERIS’ existing portfolio, enabling the combined group to strengthen its position as a leading provider of turnkey room solutions in surgical and IPT environments. The MEDIK management team will actively support the next phase of growth.
Lär dig merbioXXmed AG has sold Rancoderm GmbH to Rose Investment- und Beteiligungs AG
Rancoderm GmbH has been acquired by Rose Investment- und Beteiligungs AG to secure the funding required for the final development and market approval of its medical device DermaPro. The acquisition will enable Rancoderm to bring DermaPro to market readiness and launch it as a certified medical product for broad distribution.
Lär dig merBanook, backed by Motion Equity, has acquired Fluidda
Banook Group has acquired Fluidda NV, marking a strategic expansion into advanced in-silico trials and respiratory disease modeling. Combining Banook’s expertise in cardiac safety and clinical data services with Fluidda’s AI-driven respiratory analytics creates a powerful, integrated platform. This deal strengthens Banook’s position in the contract research organization (CRO) sector, offering pharmaceutical clients broader, technology-enabled solutions to drive drug development and reduce costs.
Lär dig mer